Rupatadine 20 mg and 40 mg are effective in reducing the symptoms of chronic cold urticaria

Acta Dermato-Venereologica

Volumn 96, Issue 1, 2016, Pages 56-59

  Abajian, Marina ^a   Curto Barredo, Laia ^b   Krause, Karoline ^a   Santamaria, Eva ^c   Izquierdo, Iñaki ^c   Church, Martin K ^a   Maurer, Marcus ^a   Giménez Arnau, Ana ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Grupo Uriach   (Spain)

Author keywords

Chronic cold urticarial; H1 antihistamine; Rupatadine; Up dosing

Indexed keywords

LIVER ENZYME; PLACEBO; RUPATADINE; CYPROHEPTADINE; HISTAMINE H1 RECEPTOR ANTAGONIST;

ARTICLE; CHRONIC URTICARIA; CLINICAL ARTICLE; COLD; COLD URTICARIA; CONTROLLED STUDY; CRITICAL STIMULATION TIME THRESHOLD; CRITICAL TEMPERATURE THRESHOLD; CROSSOVER PROCEDURE; CUTANEOUS PARAMETERS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; TEMPERATURE; TIME; TREATMENT DURATION; ADULT; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; CHRONIC DISEASE; CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY; REMISSION; SPAIN; TIME FACTOR; TREATMENT OUTCOME; URTICARIA; YOUNG ADULT;

ADULT; AGED; CHRONIC DISEASE; COLD TEMPERATURE; CROSS-OVER STUDIES; CYPROHEPTADINE; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; SPAIN; TIME FACTORS; TREATMENT OUTCOME; URTICARIA; YOUNG ADULT;

EID: 85018236327     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-2150     Document Type: Article

References (17)

1. Abajian M, Mlynek A, Maurer M. Physical urticaria. Curr Allergy Asthma Rep 2012; 12: 281–287.
2. Martinez-Escala ME, Curto-Barredo L, Carnero L, Pujol RM, Gimenez-Arnau AM. Temperature thresholds in assessment of the clinical course of acquired cold contact urticaria: a prospective observational one-year study. Acta Derm Venereol 2015; 95: 278–282.
3. Kaplan AP, Beaven MA. In vivo studies of the pathogenesis of cold urticaria, cholinergic urticaria, and vibrationinduced swelling. J Invest Dermatol 1976; 67: 327–332.
4. Magerl M, Borzova E, Gimenez-Arnau A, Grattan CE, Lawlor F, Mathelier-Fusade P, et al. The definition and diagnostic testing of physical and cholinergic urticarias–EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. Allergy 2009; 64: 1715–1721.
5. Krause K, Zuberbier T, Maurer M. Modern approaches to the diagnosis and treatment of cold contact urticaria. Curr Allergy Asthma Rep 2010; 10: 243–249.
6. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014; 69: 868–887.
7. Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol 2009; 123: 672–679.
8. Krause K, Spohr A, Zuberbier T, Church MK, Maurer M. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy 2013; 68: 921–928.
9. Metz M, Scholz E, Ferran M, Izquierdo I, Gimenez-Arnau A, Maurer M. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol 2010; 104: 86–92.
10. Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther 1997; 280: 114–121.
11. Church MK. Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males. Br J Dermatol 2010; 163: 1330–1332.
12. Izquierdo I, Merlos M, Garcia-Rafanell J. Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today (Barc) 2003; 39: 451–468.
13. Dubertret L, Zalupca L, Cristodoulo T, Benea V, Medina I, Fantin S, et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol 2007; 17: 223–228.
14. Siebenhaar F, Weller K, Mlynek A, Magerl M, Altrichter S, Vieira Dos Santos R, et al. Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clin Exp Dermatol 2007; 32: 241–245.
15. Siebenhaar F, Staubach P, Metz M, Magerl M, Jung J, Maurer M. Peltier effect-based temperature challenge: an improved method for diagnosing cold urticaria. J Allergy Clin Immunol 2004; 114: 1224–1225.
16. Di Leo E, Nettis E, Cassano N, Foti C, Delle Donne P, Vena GA, et al. Treatment of acquired cold urticaria with rupatadine. Allergy 2009; 64: 1387–1388.
17. Magerl M, Pisarevskaja D, Staubach P, Martus P, Church MK, Maurer M. Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H(1)-antihistamine dose escalation. Br J Dermatol 2012; 166: 1095–1099.